288 related articles for article (PubMed ID: 33044848)
21. Real-world treatment sequencing and healthcare costs among CLL/SLL patients treated with venetoclax.
Rogers KA; Emond B; Manceur AM; Kinkead F; Lafeuille MH; Lefebvre P; Huang Q
Curr Med Res Opin; 2021 Aug; 37(8):1409-1420. PubMed ID: 34003049
[TBL] [Abstract][Full Text] [Related]
22. Real-world analysis of adverse event rates after initiation of ibrutinib among Medicare beneficiaries with chronic lymphocytic leukemia.
Huntington SF; de Nigris E; Puckett JT; Kamal-Bahl S; Farooqui M; Ryland K; Sarpong EM; Leng S; Yang X; Doshi JA
Cancer Med; 2024 Jan; 13(2):e6953. PubMed ID: 38348963
[TBL] [Abstract][Full Text] [Related]
23. Association of Participation in the Oncology Care Model With Medicare Payments, Utilization, Care Delivery, and Quality Outcomes.
Keating NL; Jhatakia S; Brooks GA; Tripp AS; Cintina I; Landrum MB; Zheng Q; Christian TJ; Glass R; Hsu VD; Kummet CM; Woodman S; Simon C; Hassol A;
JAMA; 2021 Nov; 326(18):1829-1839. PubMed ID: 34751709
[TBL] [Abstract][Full Text] [Related]
24. Ibrutinib in Advanced Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Lower Risk of Hepatitis B Virus Reactivation.
Yang S; Zhu R; Li N; Feng Y; Zuo R; Gale RP; Huang X
Acta Haematol; 2022; 145(1):54-62. PubMed ID: 34569486
[TBL] [Abstract][Full Text] [Related]
25. Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Second-Line Setting.
Fakhri B; Emechebe N; Manzoor BS; Jawaid D; Alhasani H; Edwards M; Tuncer HH
JCO Oncol Pract; 2024 Apr; ():OP2300630. PubMed ID: 38626366
[TBL] [Abstract][Full Text] [Related]
26. What Influences the Choice of Ibrutinib-Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia?
Bravaccini S; Martinelli G; Cerchione C
Cell Transplant; 2020; 29():963689720950209. PubMed ID: 32907382
[TBL] [Abstract][Full Text] [Related]
27. Time to next treatment in patients with chronic lymphocytic leukemia initiating first-line ibrutinib or acalabrutinib.
Jacobs R; Lu X; Emond B; Morrison L; Kinkead F; Lefebvre P; Lafeuille MH; Khan W; Wu LH; Qureshi ZP; Levy MY
Future Oncol; 2024 Jan; 20(1):39-53. PubMed ID: 37476983
[TBL] [Abstract][Full Text] [Related]
28. Lifetime costs to Medicare of providing care to patients with chronic lymphocytic leukemia.
Lafeuille MH; Vekeman F; Wang ST; Kerrigan M; Menditto L; Duh MS
Leuk Lymphoma; 2012 Jun; 53(6):1146-54. PubMed ID: 22111902
[TBL] [Abstract][Full Text] [Related]
29. Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies.
Robak T; Burger JA; Tedeschi A; Barr PM; Owen C; Bairey O; Hillmen P; Simpson D; Grosicki S; Devereux S; McCarthy H; Coutre SE; Quach H; Gaidano G; Maslyak Z; Stevens DA; Moreno C; Gill DS; Flinn IW; Gribben JG; Mokatrin A; Cheng M; Styles L; James DF; Kipps TJ; Ghia P
Am J Hematol; 2018 Nov; 93(11):1402-1410. PubMed ID: 30129285
[TBL] [Abstract][Full Text] [Related]
30. Time to Second-line Treatment and Subsequent Relative Survival in Older Patients With Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Ammann EM; Shanafelt TD; Larson MC; Wright KB; McDowell BD; Link BK; Chrischilles EA
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):e11-e25. PubMed ID: 28802891
[TBL] [Abstract][Full Text] [Related]
31. Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate.
Patel C; Emond B; Lafeuille MH; Côté-Sergent A; Lefebvre P; Tandon N; El Khoury AC
Drugs Real World Outcomes; 2020 Mar; 7(1):19-29. PubMed ID: 31786737
[TBL] [Abstract][Full Text] [Related]
32. Incidence of invasive fungal infections in patients with chronic lymphocytic leukemia receiving ibrutinib within the veteran's healthcare administration.
Walker C; Horowitz A; Nooruddin Z; Frei CR
J Oncol Pharm Pract; 2024 Jun; 30(4):673-677. PubMed ID: 37309168
[TBL] [Abstract][Full Text] [Related]
33. Quality outcomes, healthcare resource utilization and costs in Medicare patients with chronic heart failure with reduced ejection fraction with and without a worsening event.
Mentz RJ; Pulungan Z; Kim S; Yang M; Teigland C; Hilkert R; Djatche LM
J Med Econ; 2021; 24(1):698-705. PubMed ID: 33900874
[TBL] [Abstract][Full Text] [Related]
34. Treatment Patterns, Healthcare Resource Utilization, and Costs of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in the US.
Yang X; Zanardo E; Lejeune D; De Nigris E; Sarpong E; Farooqui M; Laliberté F
Oncologist; 2024 Mar; 29(3):e360-e371. PubMed ID: 38280190
[TBL] [Abstract][Full Text] [Related]
35. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes.
Archibald WJ; Rabe KG; Kabat BF; Herrmann J; Ding W; Kay NE; Kenderian SS; Muchtar E; Leis JF; Wang Y; Chanan-Khan AA; Schwager SM; Koehler AB; Fonder AL; Slager SL; Shanafelt TD; Call TG; Parikh SA
Ann Hematol; 2021 Jan; 100(1):143-155. PubMed ID: 32488603
[TBL] [Abstract][Full Text] [Related]
36. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
Sharman JP; Brander DM; Mato AR; Ghosh N; Schuster SJ; Kambhampati S; Burke JM; Lansigan F; Schreeder MT; Lunin SD; Zweibach A; Shtivelband M; Travis PM; Chandler JC; Kolibaba KS; Sportelli P; Miskin HP; Weiss MS; Flinn IW
Lancet Haematol; 2021 Apr; 8(4):e254-e266. PubMed ID: 33631112
[TBL] [Abstract][Full Text] [Related]
37. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.
Soumerai JD; Ni A; Darif M; Londhe A; Xing G; Mun Y; Kay NE; Shanafelt TD; Rabe KG; Byrd JC; Chanan-Khan AA; Furman RR; Hillmen P; Jones J; Seymour JF; Sharman JP; Ferrante L; Mobasher M; Stark T; Reddy V; Dreiling LK; Bhargava P; Howes A; James DF; Zelenetz AD
Lancet Haematol; 2019 Jul; 6(7):e366-e374. PubMed ID: 31109827
[TBL] [Abstract][Full Text] [Related]
38. Cost of Disease Progression in Patients with Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, and Non-Hodgkin's Lymphoma.
Reyes C; Engel-Nitz NM; DaCosta Byfield S; Ravelo A; Ogale S; Bancroft T; Anderson A; Chen M; Matasar M
Oncologist; 2019 Sep; 24(9):1219-1228. PubMed ID: 30808814
[TBL] [Abstract][Full Text] [Related]
39. Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Barrientos JC; O'Brien S; Brown JR; Kay NE; Reddy NM; Coutre S; Tam C; Mulligan S; Jaeger U; Devereux S; Pocock C; Robak T; Schuster SJ; Schuh A; Gill D; Bloor A; Dearden C; Moreno C; Cull G; Hamblin M; Jones JA; Eckert K; Solman IG; Suzuki S; Hsu E; James DF; Byrd JC; Hillmen P
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):803-813.e7. PubMed ID: 30249389
[TBL] [Abstract][Full Text] [Related]
40. Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels.
Shanafelt TD; Borah BJ; Finnes HD; Chaffee KG; Ding W; Leis JF; Chanan-Khan AA; Parikh SA; Slager SL; Kay NE; Call TG
J Oncol Pract; 2015 May; 11(3):252-8. PubMed ID: 25804983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
